- Home
- SKIN vs RPID Comparison
SKIN vs RPID Comparison
Compare SKIN & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SKIN | RPID |
|---|---|---|
| Founded | 1997 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 202.7M | 178.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SKIN | RPID |
|---|---|---|
| Price | $1.49 | $4.05 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $2.42 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 1.0M | 124.1K |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $301,917,000.00 | $30,523,000.00 |
| Revenue This Year | N/A | $19.36 |
| Revenue Next Year | $4.30 | $21.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 16.63 |
| 52 Week Low | $0.78 | $0.87 |
| 52 Week High | $2.69 | $4.50 |
Technical Indicators
Market Signals| Indicator | SKIN | RPID |
|---|---|---|
| Relative Strength Index (RSI) | 51.84 | 54.82 |
| Support Level | $1.36 | $3.95 |
| Resistance Level | $1.35 | $4.29 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | 0.03 | -0.05 |
| Stochastic Oscillator | 55.42 | 18.75 |
Price Performance
Historical ComparisonAbout SKIN The Beauty Health Company
The Beauty Health Co is a category-creating beauty health company that along with its subsidiaries designs, develops, manufactures, markets and sells esthetic technologies and products. The company's brand portfolio includes Hydrafacial, SkinStylus, and Keravive, offering Syndeo device, SkinStylus SteriLock Microsystem, Keravive Peptide Solution and other products.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.